'); } else { var query = elem.find('.keywords').html(); $.ajax({ context: elem, url: 'https://wn.com/api/upge/cheetah-search-adv/video', cache: true, data: { 'query': query }, dataType: 'jsonp', success: function(text) { if (text.length > 0) { video_id = text[0].id; elem.find('.player').html(''); } } }); } } var stopAllYouTubeVideos = function() { var iframes = document.querySelectorAll('iframe'); Array.prototype.forEach.call(iframes, function(iframe) { iframe.contentWindow.postMessage(JSON.stringify({ event: 'command', func: 'pauseVideo' }), '*'); }); } jQuery(function() { jQuery(".playVideo").live("click", function() { if(!$(this).hasClass("played")){ stopAllYouTubeVideos(); var elem = $(this); setTimeout(function(){ mouseOverMe(elem); }, 1000); } }); jQuery(".description_box .expandContent").live("click", function() { elem = $(this).parent().parent().parent().find('.descContent'); if(elem.height() > 51) { elem.css('height', '44px'); $(this).html('Show More '); }else{ elem.css('height', 'auto'); $(this).html('Hide '); } }); jQuery('.interview-play-off').click(function() { $(".interview-play-off").hide(); $(".interview-play").show(); $(".videoplayer-control-pause").click(); }); jQuery(".video-desc .show_author_videos").live("click", function() { query = $(this).attr('title'); container = $(this).parent().parent().parent().find('.video-author-thumbs'); $(this).parent().parent().parent().find('.video-author-thumbs').css('height', '220px'); jQuery.ajax({ url: '/api/upge/cheetah-photo-search/videoresults', data: {'query': query}, success: function(text) { if(!text) { text = i18n("No results"); } container.html(jQuery(text)); } }); }); }); // -->

Latest News for: phase 1 clinical trial

Edit

Nature Cell Advances Accelerated Approval and Phase 3 Clinical Trial Strategy for JointStem, Outlines Nasdaq ...

ACCESSWIRE 27 Mar 2026
Building on its Breakthrough Therapy designation, the company is preparing for an FDA meeting in May 2026 to concretize its accelerated approval strategy and finalize Phase 3 clinical trial design.
Edit

Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 ...

Nasdaq Globe Newswire 26 Mar 2026
Highlights advancement of first-in-class neuroprotective candidate targeting demyelination. Highlights advancement of first-in-class neuroprotective candidate targeting demyelination ... .
Edit

Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging

Pharmiweb 26 Mar 2026
The recently completed Phase 1 clinical trial, conducted in ... Our lead drug candidate – RLS-1496, a potential first-in-class disease-modifying GPX4 modulator – is currently in Phase I clinical trials.
Edit

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204

Nasdaq Globe Newswire 25 Mar 2026
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist ... .
Edit

Callio Therapeutics Doses First Patient in Phase I Clinical Trial of Dual-Payload ADC CLIO-8221 in ...

Nasdaq Globe Newswire 24 Mar 2026
Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumors ... .
Edit

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer (Form 8-K) (Silexion Therapeutics Corp)

Public Technologies 24 Mar 2026
The Company also plans to submit a Phase 2/3 clinical trial application in Germany by the end of this current quarter, with additional regulatory filings across the European Union planned in early 2027.
Edit

Causeway Therapeutics Presents Data from Phase 2 Clinical Trial of TenoMiR� for Lateral Epicondylitis at ...

Nasdaq Globe Newswire 19 Mar 2026
Causeway Therapeutics announces the presentation of data from its Phase 2 clinical trial evaluating TenoMiR� (CWT-001), at RNA Leaders Europe 2026 ... .
Edit

Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease

Pharmiweb 19 Mar 2026
Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first patients were enrolled in Esprit, a global Phase 2 clinical trial evaluating S-606001, an investigational drug for the treatment of late-onset Pompe disease (LOPD).
×